Target Name: FER
NCBI ID: G2241
Other Name(s): proto-oncogene c-Fer | Tyrosine-protein kinase Fer (isoform a) | fujinami poultry sarcoma/Feline sarcoma-related protein Fer | FerT | TYK3 | Feline encephalitis virus-related kinase FER | Proto-oncogene c-Fer | p94-FER | protein phosphatase 1, regulatory subunit 74 | Proto-oncogene tyrosine-protein kinase FER | FER tyrosine kinase | FER tyrosine kinase, transcript variant 1 | FER variant 1 | FER_HUMAN | Fujinami poultry sarcoma/Feline sarcoma-related protein Fer | p47 | Tyrosine-protein kinase Fer | Tyrosine kinase 3 | fer (fps/fes related) tyrosine kinase | phosphoprotein NCP94 | p94-Fer | feline encephalitis virus-related kinase FER | c-FER | PPP1R74 | tyrosine kinase 3

FER as a Potential Drug Target: Unlocking the Potential of Proto-Oncogene c-Fer

Introduction

Cancer is one of the leading causes of morbidity and mortality worldwide, and the development of new therapeutic approaches to combat this disease is crucial. One promising candidate for cancer treatment is the proto-oncogene c-Fer, which has been identified as a potential drug target. In this article, we will explore the science behind c-Fer and its potential as a drug target, as well as the current research and development efforts in this field.

Science Behind c-Fer

c-Fer, also known as ferroptide, is a protein that is expressed in various tissues throughout the body, including the brain, heart, kidneys, and liver. It is composed of four beta-strands that are held together by disulfide bonds. The The most abundant and well-studied form of c-Fer is the alpha-helical transmembrane protein known as c-Fer伪. This protein plays a critical role in various physiological processes, including blood clotting, inflammation, and cell signaling.

One of the unique features of c-Fer is its proto-oncogene nature. This means that c-Fer can promote the growth and transformation of cancer cells. In fact, studies have shown that c-Fer is overexpressed in various types of cancer, including breast, lung, and colorectal cancer. This overexpression phenomenon makes c-Fer a very attractive drug target.

Drug Target Potential

c-Fer's proto-oncogene nature makes it an attractive target for cancer treatment. One of the main advantages of targeting c-Fer is its ability to induce apoptosis (programmed cell death) in cancer cells. This process is regulated by various signaling pathways, including the T cell-mediated apoptosis pathway. By inhibiting the activity of the T cell receptor (TCR), which is a critical signaling pathway for cancer cells, c-Fer has been shown to induce apoptosis in cancer cells.

Another potential mechanism by which c-Fer can be targeted is its role in the regulation of cell adhesion. c-Fer has been shown to play a critical role in the regulation of cell-cell adhesion, and its overexpression has been linked to the development of various types of cancer. This function of c-Fer makes it a potential drug target for cancer treatment.

Current Research and Development Efforts

At present, drug research on c-Fer mainly focuses on two aspects: inhibiting the activity of c-Fer and treating tumor cells overexpressing c-Fer.

First, researchers are exploring ways to treat cancer by inhibiting the activity of c-Fer. This involves using small molecule compounds, proteins or peptides to bind to the active site of c-Fer, thereby inhibiting its function. In addition, researchers are exploring ways to treat cancer by modulating the activity of c-Fer. This includes using drugs to inhibit overexpression of c-Fer, or using gene editing technology to excise the c-Fer gene.

Second, researchers are exploring ways to target cancer cells that overexpress c-Fer. This includes the use of immunotherapy to enhance tumor cell responses to vaccines, and the use of chemotherapy to kill tumor cells that overexpress c-Fer. In addition, researchers are exploring the use of radioembolization agents to block the blood supply of c-Fer-overexpressing tumor cells.

Conclusion

c-Fer is a very attractive drug target because its proto-oncogene properties and cell signaling pathways make it a promising direction for cancer treatment. Currently, drug research on c-Fer mainly focuses on inhibiting its activity or overexpressing tumor cells.

Protein Name: FER Tyrosine Kinase

Functions: Tyrosine-protein kinase that acts downstream of cell surface receptors for growth factors and plays a role in the regulation of the actin cytoskeleton, microtubule assembly, lamellipodia formation, cell adhesion, cell migration and chemotaxis. Acts downstream of EGFR, KIT, PDGFRA and PDGFRB. Acts downstream of EGFR to promote activation of NF-kappa-B and cell proliferation. May play a role in the regulation of the mitotic cell cycle. Plays a role in the insulin receptor signaling pathway and in activation of phosphatidylinositol 3-kinase. Acts downstream of the activated FCER1 receptor and plays a role in FCER1 (high affinity immunoglobulin epsilon receptor)-mediated signaling in mast cells. Plays a role in the regulation of mast cell degranulation. Plays a role in leukocyte recruitment and diapedesis in response to bacterial lipopolysaccharide (LPS). Plays a role in synapse organization, trafficking of synaptic vesicles, the generation of excitatory postsynaptic currents and neuron-neuron synaptic transmission. Plays a role in neuronal cell death after brain damage. Phosphorylates CTTN, CTNND1, PTK2/FAK1, GAB1, PECAM1 and PTPN11. May phosphorylate JUP and PTPN1. Can phosphorylate STAT3, but the biological relevance of this depends on cell type and stimulus

More Common Targets

FER1L4 | FER1L5 | FER1L6 | FER1L6-AS1 | FER1L6-AS2 | FERD3L | FERMT1 | FERMT2 | FERMT3 | Ferritin | FES | Fetal Hemoglobin (HbF) | FETUB | FEV | FEZ1 | FEZ2 | FEZF1 | FEZF1-AS1 | FEZF2 | FFAR1 | FFAR2 | FFAR3 | FFAR4 | FGA | FGB | FGD1 | FGD2 | FGD3 | FGD4 | FGD5 | FGD5-AS1 | FGD5P1 | FGD6 | FGF1 | FGF10 | FGF10-AS1 | FGF11 | FGF12 | FGF12-AS2 | FGF13 | FGF13-AS1 | FGF14 | FGF14-AS1 | FGF14-AS2 | FGF14-IT1 | FGF16 | FGF17 | FGF18 | FGF19 | FGF2 | FGF20 | FGF21 | FGF22 | FGF23 | FGF3 | FGF4 | FGF5 | FGF6 | FGF7 | FGF7P3 | FGF7P5 | FGF7P6 | FGF8 | FGF9 | FGFBP1 | FGFBP2 | FGFBP3 | FGFR1 | FGFR1OP2 | FGFR2 | FGFR3 | FGFR3P1 | FGFR4 | FGFRL1 | FGG | FGGY | FGL1 | FGL2 | FGR | FH | FHAD1 | FHDC1 | FHF Complex | FHIP1A | FHIP1B | FHIP2A | FHIP2B | FHIT | FHL1 | FHL2 | FHL3 | FHL5 | FHOD1 | FHOD3 | FIBCD1 | FIBIN | FIBP | Fibrinogen | Fibroblast growth factor (FGF) | Fibroblast Growth Factor Receptor (FGFR)